FDA approves drug for rare cholesterol disorder

Author(s):

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here